New Market Research Report: Belarus Pharmaceuticals & Healthcare Report Q1 2016

Despite high forecasted growth in pharmaceutical sales and healthcare expenditure, Belarus will fail to attract investment from foreign pharmaceutical firms. Government policy to promote the use of domestically-produced medicines will cause a slowdown in pharmaceutical imports and the country's investment appeal will be further dampened by an unstable currency and rising regional political tensions.

Headline Expenditure Projections

Pharmaceuticals: BYR10,405bn in 2014 (USD1.02bn) to BYR12,247bn (USD801mn) in 2015; +17.7% in local currency terms and -21.2% in US dollar terms.
Healthcare: BYR48,816bn (USD4.76bn) in 2014 to BYR60,395bn (USD3.95bn) in 2015; +23.7% in local currency terms and -17.1% in US dollar terms.

Risk/Reward Index

Belarus has a Risk Reward Index (RRI) score of 45.1, below the regional average of 49.6, making it the 15th most attractive market in the Central and Eastern European region. Belarus scores well below the regional average for Risks on account of its economic instability and unfavourable pharmaceutical regulatory environment. These factors are key contributors to its low standing in our index.

Full Report Details at
- http://www.fastmr.com/prod/1082730_belarus_pharmaceuticals.aspx?afid=301

Latest Updates

In November 2015, Belarusian and Pakistani government representatives signed a number of trade contracts, with particular focus on pharmaceuticals, worth initially about USD55mn but hoped to reach USD1bn in the future

The Belarus Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belarus Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belarus pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Belarus, to test other views - a key input for successful budgeting and strategic business planning in the Belarusian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Belarusian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belarus.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Oman Pharmaceuticals & Healthcare Report Q1 2016